

National Personal Injury Lawyers, TorHoerman Law, Provides Diabetes Drug Lawsuit Update

CHICAGO, IL, USA, August 27, 2013 /EINPresswire.com/ -- Yesterday, a panel of federal judges entered an <u>order consolidating</u> all Byetta, Januvia, Janumet and Victoza cases into one courtroom in the Southern District of California under the title In re:Incretin Mimetics-Based Therapies Products Liability Litigation.

Litigation over diabetes drugs that manage blood insulin levels, referred to as Incretin Mimetics, continues to move forward. In April, an <u>independent body</u> released the results of its research indicating that the incretin mimetics, known commercially as Byetta, Januvia, Janumet and Victoza, may carry up to 25 times the risk of developing <u>pancreatic cancer</u> for patients taking these drugs. Plaintiffs and their families throughout the Country have alleged that they now suffer or have died from pancreatic cancer as a result of taking these types of drugs.

Yesterday, a panel of federal judges entered an order consolidating all current and future Byetta, Januwia, Janumet and Victoza cases into one courtroom in the Southern District of California under the title In re:Incretin Mimetics-Based Therapies Products Liability Litigation.

Given the complexity of this litigation and anticipated resource demands that accompany "mass tort" (multiple plaintiffs injured in a similar fashion by a defective product) cases, the consolidation is intended to allow the litigation to move forward in an efficient, organized and timely manner.

According to the Transfer Order filed on August 26, 2013, the 53 actions currently pending in seven districts will be transferred to the courtroom of the Honorable Anthony J. Battaglia for coordinated or consolidated pretrial proceedings in MDL No. 2452. The attorneys at TorHoerman Law expect the number of cases filed to increase substantially now that the forum has been decided.

After receiving word of the consolidation, Tor Hoerman, attorney and founding partner of TorHoerman Law stated "we are pleased with the panel's decision today and look forward to the opportunity to see that justice is done for those injured as a result of taking Byetta, Januvia, Janumet and Victoza."

TorHoerman Law is urging anyone diagnosed with pancreatic cancer while on Byetta, Januvia,

Janumet or Victoza to contact an experienced attorney soon to investigate whether you have a right to compensation for your diagnosis.

TorHoerman Law is a national drug, medical device and toxic tort law firm. Representing clients in 50 states, we are not afraid to take on the largest companies when they put profits ahead of safety.

Jessica Hoerman TorHoerman Law 618-656-4400 email us here

This press release can be viewed online at: https://www.einpresswire.com/article/165072598

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2024 Newsmatics Inc. All Right Reserved.